Everolimus induces Met inactivation by disrupting the FKBP12/Met complex

Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment strategy for several cancer types. Rapamycin derivatives such as everolimus are allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin FKBP12, a prolyl isomerase with different cellul...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Raimondo, Lucia, D'Amato, Valentina, Servetto, Alberto, Rosa, Roberta, Marciano, Roberta, Formisano, Luigi, Mauro, Concetta Di, Orsini, Roberta Clara, Cascetta, Priscilla, Ciciola, Paola, De Maio, Ana Paula, Di Renzo, Maria Flavia, Cosconati, Sandro, Bruno, Agostino, Randazzo, Antonio, Napolitano, Filomena, Montuori, Nunzia, Veneziani, Bianca Maria, Placido, Sabino De, Bianco, Roberto
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2016
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129993/
https://ncbi.nlm.nih.gov/pubmed/27223077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9484
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים